$1.05
-0.08 (-7.08%)
Open$1.13
Previous Close$1.13
Day High$1.14
Day Low$1.03
52W High$3.40
52W Low$0.71
Volume—
Avg Volume162.5K
Market Cap35.20M
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,252.4% upside
Current
$1.05
$1.05
Target
$24.70
$24.70
$17.28
$24.70 avg
$43.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.17M | 1.04M | 9.21M |
| Net Income | -11,243,139 | -9,012,134 | 1.19M |
| Profit Margin | -962.1% | -914.0% | 12.9% |
| EBITDA | -9,709,254 | -8,214,990 | 1.73M |
| Free Cash Flow | — | — | 900.3K |
| Rev Growth | +12.3% | +12.3% | -0.3% |
| Debt/Equity | 1.46 | 1.46 | 0.87 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |